HLA-F explained

HLA class I histocompatibility antigen, alpha chain F is a protein that in humans is encoded by the HLA-F gene.^{[1] [2]} It is an empty intracellular molecule that encodes a non-classical heavy chain anchored to the membrane and forming a heterodimer with a β-2 microglobulin light chain. It belongs to the HLA class I heavy chain paralogues that separate from most of the HLA heavy chains. HLA-F is localized in the endoplasmic reticulum and Golgi apparatus, and is also unique in the sense that it exhibits few polymorphisms in the human population relative to the other HLA genes; however, there have been found different isoforms from numerous transcript variants found for the HLA-F gene. Its pathways include IFN-gamma signaling and CDK-mediated phosphorylation (cyclin-dependent kinase) and removal of the Saccharomyces cerevisiae Cdc6 protein, which is crucial for functional DNA replication.

HLA-F

The Major Histocompatibility Complex (MHC) is a group of cell surface proteins that in humans is also called the Human Leukocyte Antigen (HLA) complex. These proteins are encoded by a cluster of genes known as the HLA locus. The HLA locus occupies a ~ 3Mbp stretch that is located on the short arm of chromosome 6, specifically on 6p21.1-21.3.^[3] The MHC proteins are classified into three main categories, namely class I, II, and III. There are over 140 genes within the HLA locus and they are often called HLA genes.^[4] HLA-A, B, and C are the classical class I genes and HLA-E, F and G are the nonclassical class I genes.^{[5] [1]} The protein encoded from the gene HLA-F was originally isolated from the human lymphoblastoid cell line 721.^[6]

Gene

The HLA-F gene is located on the short arm of chromosome 6, telomeric to the HLA-A locus. HLA-F has little allelic polymorphism^[7] and is highly conserved in other primates.^[8] HLA-F appears to be a recombinant between two multigene families, one that comprises conserved sequences found in all class I proteins (single transmembrane span) and another distinct family of genes with a conserved 3’ UTR. Many of these genes are highly transcribed and differentially expressed. The heavy chain gene contains 8 exons. Exon one encodes the leader peptide, exons 2 and 3 encode the alpha1 and alpha2 domains, the putative peptide binding sites, exon 4 encodes the alpha3 domain, exon 5 and 6 encode the transmembrane region and exons 7 and 8 the cytoplasmic tail. However, exons 7 and 8 (the cytoplasmic tail) are not translated due to an in-frame translation termination codon in exon 6.^[2]

Protein

The HLA-F protein is a ~40-41 kDa molecule with conserved domains.^[9] Exon 7 is absent from the mRNA of HLA-F.^[10] The absence of this exon produces a modification in the cytoplasmic tail of the protein making it shorter relative to classical HLA class-I proteins. The cytoplasmic tail helps HLA-F exit the endoplasmic reticulum,^[11] and that function is primarily done by the amino acid valine found at the C-terminal end of the tail.^[12]

Structure

The structure of HLA-F is similar to that of the other HLA class I genes, which consist of eight exons.  Of the key residues likely to form from the floor of the groove, position 97 is a glycine whose residue is a single proton, whereas in most class Ia structures it is a charged residue and in HLA-E, it is a bulky hydrophobic tryptophan. If the HLA-F groove binds to a peptide, then the glycine residue will create space in the mid-portion of the groove which might allow larger side chains to fit and be accommodated . This nonclassical class I gene also has two histidine residues (His 114-His116) close together in the C-terminal groove floor, mirroring His-9-His99 in HLA-E. Tyr 7, Tyr 59, Tyr 159 and Tyr 171, which are typically involved in the hydrogen-bonding network to the peptide N-terminal residues, are conserved.^[13]

The possible pocket regions of HLA-F include a situation where the A pocket is hydrophobic and similar to that of HLA-E, and pocket B retains Met 45 and Ala 67, which also characterize the HLA-E pocket and are likely to be hydrophobic and large. The C-pocket, however, differs significantly from that of the HLA-E with similarities to the C pocket of HLA-B8. In the D pocket region of this protein, the Asn 99 may favor a charged residue, but the other residues in this pocket, including phenylalanine make predictions hard to make. However, the F-pocket of HLA-F appears well conserved with HLA-E and the other class Ia molecules and likely favors an aliphatic group, such as leucine.^[14]

Expression

Classic HLA class I molecules interact with HLA-F through their heavy chain. However, HLA class I molecules only interact with HLA-F when they are in the form of an open conformer (free of peptide). Thus, HLA-F is expressed independently of bound peptide.^[15]

Intracellular expression

HLA-F is expressed intracellularly in peripheral blood lymphocytes (PBL), resting lymphocyte cells (B, T, NK, and monocytes), tonsils, spleen, thymus, bladder, brain, colon, kidney, liver, lymphoblast, T cell leukemia, choriocarcinoma, and carcinoma.^{[16] [17]}

Extracellular expression

HLA-F is expressed on the cell surface of activated lymphocytes, HeLa cells, EBV-transformed lymphoblastoid cells, and in some activated monocyte cell lines. The surface expression of HLA-F coincides with the activated immune response since HLA-F is mostly found on the surface of stimulated T memory cells but not on circulating regulatory T cells.^[18]

Expression during pregnancy

In the first trimester, HLA-F is weakly expressed in the trophoblastic elements residing outside the villi (extravillous trophoblast cells). Its expression increases and translocated onto the cell surface during the second trimester, coinciding with fetal growth which, in context, suggests it plays a role in development.^[19]

Interaction with NK cells

HLA-F can be expressed in two ways on the cell surface: with  β2m and a peptide as a complex of HLA-F heavy chain  or without the peptide and  β2m as an open conformer with just the heavy chain. It can transport from the endoplasmic reticulum partially with the aid of tapasin, independent from the TAP protein complex, typically associated with antigen processing and transportation. Open conformer (OC) HLA-Fs can form homodimers and heterodimers with distinct HLA class I OCs, which may suggest they are involved in cross-presentation of extracellular antigens.^[20]

HLA OCs are able to bind to other receptors than the HLA complex with the β2m and peptide, most relevant to the diverse function of HLA-F. These receptors include binding inhibitory and activating immune receptors primarily expressed in natural killer (NK) cells, but also includes other immune cells. To do this, HLA OCs bind to the activating receptor KIR3DS1 and inhibitory receptor killer receptors 3DL1 and 3dL2.^[14]

Recent studies further suggest that HLA-F also presents long peptides (7 to more than 30 amino acids) to T cell receptors. They are able to do this because of an amino acid substitution in position 62 that forms an open-ended groove with N-terminal extensions. It is still not known if there may be consequences for this in the immune regulation at the feto-maternal contact zone.

Transcriptional regulation of HLA-F

In the promoter of HLA-F, both studied regulatory modules display homology to the classical MHC class I genes. HLA-F has a conserved κB1 site enhancer bound by NF- κB, but the HLA-F gene is not induced by NF- κB without flanking regulatory sequences (such as IRSE) that provide a helper function. The IRSE in HLA-F is homologous to other classical MHC class I genes.  INF- γ also induces HLA-F with its IRSE (IFN-stimulated response element). Further, it is also induced by CIITA, a transcriptional coactivator that regulates the transcription of MHC class II genes.^[21]

Function

HLA-F is currently the most enigmatic of the HLA molecules. Hence, its precise functions still remain to be resolved. Though, in contrast to other HLA molecules, it mainly resides intracellularly and rarely reaches the cell surface, e.g. upon activation of NK, B and T cells. Unlike classical HLA class I molecules, which possess ten highly conserved amino acids responsible for antigen recognition, HLA-F only has 5, suggesting a biological function different from peptide presentation. Upon immune cell activation, HLA-F binds free forms of HLA class I molecules and reaches the cell surface as heterodimer. In this way HLA-F stabilizes HLA class I molecules that haven't yet bound peptides, thereby acting as a chaperone and transporting the free HLA class I to, on, and from the cell surface.^[22]

Association with specialized ligands

HLA-F has been observed only in a subset of cell membranes, mostly B cells and activated lymphocytes. As a result, it has been suggested that its role involves association with specialized ligands that become available in the cell membrane of activated cells. For example, HLA-F can act as a peptide binding of ILT2 and ILT4.^[23] HLA-F can associate with TAP (transporter associated with antigen processing) and with the multimeric complex involved in peptide loading.

Maternal immunity tolerance

It has been observed that all three non-classical HLA class I proteins are expressed in placental trophoblasts in contact with maternal immune cells. This suggests that these proteins collaborate in the immune response and that HLA-F plays a fundamental role in both normal and maternal immune response. HLA-F is also expressed in decidual extravillous trophoblasts. During pregnancy, HLA-F interacts with T reg cells and extravillous trophoblasts mediating maternal tolerance to the fetus.

Intermolecular communication

During the interaction between HLA-F and the heavy chain (HC) of HLA class I molecules in activated lymphocytes, HLA-F plays a role as a chaperone, escorting HLA class I HC to the cell surface and stabilizing its expression in the absence of peptide. HLA-F binds most allelic forms of HLA class I open conformers, but it does not bind peptide complexes.

The expression patterns of HLA-F in T cells suggest that HLA-F is involved in the communication pathway between T reg and activated T cells, where HLA-F signals that the immune response has been activated. During this communication, either HLA-F invokes secretion of inhibitory cytokines by the regulatory T cells or it provides a simple inhibitory signal to the regulatory T cells, allowing a normal immune response to proceed.

Exogenous antigen cross-presentation

Viral proteins and other exogenous antigens decrease surface HLA-F expression because the exogenous proteins interact with HLA class I molecules at the same sites where HLA-F interacts, producing crosslinking. The exogenous proteins trigger an internal co-localization of both HLA-F and HLA class I molecules. Exogenous proteins with higher affinity will interact more readily with HLA class I molecules triggering a dissociation of HLA class I/HLA-F, thereby reducing the surface levels of HLA-F. HLA-F interacts with the open conformer (OC) of HLA class I and they function together in cross-presentation of exogenous antigen. Exogenous antigen binds to a structure on the surface of activated cells; this structure is composed of HLA class I open conformer and HLA-F; the peptide-binding point of contact is a specific HLA class I epitope on the exogenous antigen.

Ligand during inflammatory response

The complex HLA-F/HLA class I OC has two distinct roles that are central to the inflammatory response: first, it is a ligand for KIR receptors and can both activate and inhibit KIR; second, it is involved in cross-presentation of exogenous antigen.^{[24] [25] [14]}

The complex HLA-F/HLA class-I OC is a ligand for a subset of KIR (Killer-cell immunoglobulin-like receptor) receptors. Specifically, it was demonstrated that HLA-F interacts physically and functionally with three KIR receptors: KIR3DL2, KIR2DS4, and KIR3DS1, particularly during the inflammatory response. KIR directly interacts with both HLA-F and HLA class-I individually (i.e. no dimerization between HLA-F and HLA class-I is necessary).

Disease association

HLA-F has been linked to several diseases (Table). For cancer and tumors, HLA-F expression has been found to be enhanced in gastric adenocarcinoma,^[26] breast cancer,^[27] esophageal carcinoma,^[28] lung cancer,^[29] hepatocellular carcinoma,^[30] and neuroblastoma.^[31] HLA-F has also been associated with susceptibility to several diseases: hepatitis B,^[32] Systemic Lupus Erythematosus,^[33] and Type 1 diabetes (T1D).^[34]

Disease associations!disease!reference

gastric adenocarcinoma
breast cancer
esophageal carcinoma
lung cancer
hepatocellular carcinoma
neuroblastoma
hepatitis B
Systemic Lupus Erythematosus
Type 1 Diabetes

Further reading

• Geyer M, Fackler OT, Peterlin BM . Structure--function relationships in HIV-1 Nef . EMBO Reports . 2 . 7 . 580–585 . July 2001 . 11463741 . 1083955 . 10.1093/embo-reports/kve141 .
• Greenway AL, Holloway G, McPhee DA, Ellis P, Cornall A, Lidman M . HIV-1 Nef control of cell signalling molecules: multiple strategies to promote virus replication . Journal of Biosciences . 28 . 3 . 323–335 . April 2003 . 12734410 . 10.1007/BF02970151 . 33749514 .
• Bénichou S, Benmerah A . [The HIV nef and the Kaposi-sarcoma-associated virus K3/K5 proteins: "parasites"of the endocytosis pathway] . Médecine/Sciences. 19 . 1 . 100–106 . January 2003 . 12836198 . 10.1051/medsci/2003191100 . free .
• Leavitt SA, SchOn A, Klein JC, Manjappara U, Chaiken IM, Freire E . Interactions of HIV-1 proteins gp120 and Nef with cellular partners define a novel allosteric paradigm . Current Protein & Peptide Science . 5 . 1 . 1–8 . February 2004 . 14965316 . 10.2174/1389203043486955 .
• Tolstrup M, Ostergaard L, Laursen AL, Pedersen SF, Duch M . HIV/SIV escape from immune surveillance: focus on Nef . Current HIV Research . 2 . 2 . 141–151 . April 2004 . 15078178 . 10.2174/1570162043484924 .
• Joseph AM, Kumar M, Mitra D . Nef: "necessary and enforcing factor" in HIV infection . Current HIV Research . 3 . 1 . 87–94 . January 2005 . 15638726 . 10.2174/1570162052773013 .
• Anderson JL, Hope TJ . HIV accessory proteins and surviving the host cell . Current HIV/AIDS Reports . 1 . 1 . 47–53 . April 2004 . 16091223 . 10.1007/s11904-004-0007-x . 34731265 .
• Kozlowski S, Corr M, Takeshita T, Boyd LF, Pendleton CD, Germain RN, Berzofsky JA, Margulies DH . 6 . Serum angiotensin-1 converting enzyme activity processes a human immunodeficiency virus 1 gp160 peptide for presentation by major histocompatibility complex class I molecules . The Journal of Experimental Medicine . 175 . 6 . 1417–1422 . June 1992 . 1316930 . 2119225 . 10.1084/jem.175.6.1417 .
• Lury D, Epstein H, Holmes N . The human class I MHC gene HLA-F is expressed in lymphocytes . International Immunology . 2 . 6 . 531–537 . 1991 . 1707659 . 10.1093/intimm/2.6.531 .
• Takahashi H, Merli S, Putney SD, Houghten R, Moss B, Germain RN, Berzofsky JA . A single amino acid interchange yields reciprocal CTL specificities for HIV-1 gp160 . Science . 246 . 4926 . 118–121 . October 1989 . 2789433 . 10.1126/science.2789433 . 1989Sci...246..118T .
• Dianzani U, Bragardo M, Buonfiglio D, Redoglia V, Funaro A, Portoles P, Rojo J, Malavasi F, Pileri A . 6 . Modulation of CD4 lateral interaction with lymphocyte surface molecules induced by HIV-1 gp120 . European Journal of Immunology . 25 . 5 . 1306–1311 . May 1995 . 7539755 . 10.1002/eji.1830250526 . 37717142 .
• Howcroft TK, Palmer LA, Brown J, Rellahan B, Kashanchi F, Brady JN, Singer DS . HIV Tat represses transcription through Sp1-like elements in the basal promoter . Immunity . 3 . 1 . 127–138 . July 1995 . 7621073 . 10.1016/1074-7613(95)90165-5 . free .
• Chen YH, Böck G, Vornhagen R, Steindl F, Katinger H, Dierich MP . HIV-1 gp41 enhances major histocompatibility complex class I and ICAM-1 expression on H9 and U937 cells . International Archives of Allergy and Immunology . 104 . 3 . 227–231 . July 1994 . 7913356 . 10.1159/000236670 .
• Chen YH, Böck G, Vornhagen R, Steindl F, Katinger H, Dierich MP . HIV-1 gp41 binding proteins and antibodies to gp41 could inhibit enhancement of human Raji cell MHC class I and II expression by gp41 . Molecular Immunology . 31 . 13 . 977–982 . September 1994 . 8084338 . 10.1016/0161-5890(94)90092-2 .
• Maruyama K, Sugano S . Oligo-capping: a simple method to replace the cap structure of eukaryotic mRNAs with oligoribonucleotides . Gene . 138 . 1–2 . 171–174 . January 1994 . 8125298 . 10.1016/0378-1119(94)90802-8 .
• Howcroft TK, Strebel K, Martin MA, Singer DS . Repression of MHC class I gene promoter activity by two-exon Tat of HIV . Science . 260 . 5112 . 1320–1322 . May 1993 . 8493575 . 10.1126/science.8493575 . 1993Sci...260.1320H .
• Gasparini P, Borgato L, Piperno A, Girelli D, Olivieri O, Gottardi E, Roetto A, Dianzani I, Fargion S, Schinaia G . 6 . Linkage analysis of 6p21 polymorphic markers and the hereditary hemochromatosis: localization of the gene centromeric to HLA-F . Human Molecular Genetics . 2 . 5 . 571–576 . May 1993 . 8518796 . 10.1093/hmg/2.5.571 .
• Schwartz O, Maréchal V, Le Gall S, Lemonnier F, Heard JM . Endocytosis of major histocompatibility complex class I molecules is induced by the HIV-1 Nef protein . Nature Medicine . 2 . 3 . 338–342 . March 1996 . 8612235 . 10.1038/nm0396-338 . 7461342 .
• Alexander-Miller MA, Parker KC, Tsukui T, Pendleton CD, Coligan JE, Berzofsky JA . Molecular analysis of presentation by HLA-A2.1 of a promiscuously binding V3 loop peptide from the HIV-envelope protein to human cytotoxic T lymphocytes . International Immunology . 8 . 5 . 641–649 . May 1996 . 8671651 . 10.1093/intimm/8.5.641 . free .

Notes and References

1. Geraghty DE, Wei XH, Orr HT, Koller BH . Human leukocyte antigen F (HLA-F). An expressed HLA gene composed of a class I coding sequence linked to a novel transcribed repetitive element . The Journal of Experimental Medicine . 171 . 1 . 1–18 . January 1990 . 1688605 . 2187653 . 10.1084/jem.171.1.1 .
2. Web site: Entrez Gene: HLA-F major histocompatibility complex, class I, F.
3. Book: Lewin's GENES XI . Chapter 18: Somatic recombination and hypermutation in the immune system . https://books.google.com/books?id=yXFfPkLq4yEC&q=Somatic+recombination+and+hypermutation+in+the+immune+system&pg=PA459 . Krebs . J.E. . Goldstein . E.S. . Kilpatrick . S.T. . vanc . Jones & Bartlett Learning . 2014 . 978-1-4496-5985-1 . USA . 459–99 .
4. Smith WP, Vu Q, Li SS, Hansen JA, Zhao LP, Geraghty DE . Toward understanding MHC disease associations: partial resequencing of 46 distinct HLA haplotypes . Genomics . 87 . 5 . 561–571 . May 2006 . 16434165 . 10.1016/j.ygeno.2005.11.020 . free .
5. Koller BH, Geraghty DE, DeMars R, Duvick L, Rich SS, Orr HT . Chromosomal organization of the human major histocompatibility complex class I gene family . The Journal of Experimental Medicine . 169 . 2 . 469–480 . February 1989 . 2562983 . 2189218 . 10.1084/jem.169.2.469 .
6. Geraghty DE, Koller BH, Orr HT . A human major histocompatibility complex class I gene that encodes a protein with a shortened cytoplasmic segment . Proceedings of the National Academy of Sciences of the United States of America . 84 . 24 . 9145–9149 . December 1987 . 3480534 . 299709 . 10.1073/pnas.84.24.9145 . 1987PNAS...84.9145G . free .
7. Pyo CW, Williams LM, Moore Y, Hyodo H, Li SS, Zhao LP, Sageshima N, Ishitani A, Geraghty DE . 6 . HLA-E, HLA-F, and HLA-G polymorphism: genomic sequence defines haplotype structure and variation spanning the nonclassical class I genes . Immunogenetics . 58 . 4 . 241–251 . May 2006 . 16570139 . 10.1007/s00251-005-0076-z . 22308414 .
8. Daza-Vamenta R, Glusman G, Rowen L, Guthrie B, Geraghty DE . Genetic divergence of the rhesus macaque major histocompatibility complex . Genome Research . 14 . 8 . 1501–1515 . August 2004 . 15289473 . 509259 . 10.1101/gr.2134504 .
9. Wainwright SD, Biro PA, Holmes CH . HLA-F is a predominantly empty, intracellular, TAP-associated MHC class Ib protein with a restricted expression pattern . Journal of Immunology . 164 . 1 . 319–328 . January 2000 . 10605026 . 10.4049/jimmunol.164.1.319 . free .
10. O'Callaghan CA, Bell JI . Structure and function of the human MHC class Ib molecules HLA-E, HLA-F and HLA-G . Immunological Reviews . 163 . 129–138 . June 1998 . 9700506 . 10.1111/j.1600-065x.1998.tb01192.x . 6160579 .
11. Boyle LH, Gillingham AK, Munro S, Trowsdale J . Selective export of HLA-F by its cytoplasmic tail . Journal of Immunology . 176 . 11 . 6464–6472 . June 2006 . 16709803 . 10.4049/jimmunol.176.11.6464 . free .
12. Goodridge JP, Burian A, Lee N, Geraghty DE . HLA-F complex without peptide binds to MHC class I protein in the open conformer form . Journal of Immunology . 184 . 11 . 6199–6208 . June 2010 . 20483783 . 3777411 . 10.4049/jimmunol.1000078 .
13. Sim MJ, Sun PD . HLA-F: A New Kid Licensed for Peptide Presentation . English . Immunity . 46 . 6 . 972–974 . June 2017 . 28636965 . 10.1016/j.immuni.2017.06.004 . free .
14. Garcia-Beltran WF, Hölzemer A, Martrus G, Chung AW, Pacheco Y, Simoneau CR, Rucevic M, Lamothe-Molina PA, Pertel T, Kim TE, Dugan H, Alter G, Dechanet-Merville J, Jost S, Carrington M, Altfeld M . 6 . Open conformers of HLA-F are high-affinity ligands of the activating NK-cell receptor KIR3DS1 . Nature Immunology . 17 . 9 . 1067–1074 . September 2016 . 27455421 . 4992421 . 10.1038/ni.3513 .
15. Goodridge JP, Lee N, Burian A, Pyo CW, Tykodi SS, Warren EH, Yee C, Riddell SR, Geraghty DE . 6 . HLA-F and MHC-I open conformers cooperate in a MHC-I antigen cross-presentation pathway . Journal of Immunology . 191 . 4 . 1567–1577 . August 2013 . 23851683 . 3732835 . 10.4049/jimmunol.1300080 .
16. Lee N, Geraghty DE . HLA-F surface expression on B cell and monocyte cell lines is partially independent from tapasin and completely independent from TAP . Journal of Immunology . 171 . 10 . 5264–5271 . November 2003 . 14607927 . 10.4049/jimmunol.171.10.5264 . free .
17. Lepin EJ, Bastin JM, Allan DS, Roncador G, Braud VM, Mason DY, van der Merwe PA, McMichael AJ, Bell JI, Powis SH, O'Callaghan CA . 6 . Functional characterization of HLA-F and binding of HLA-F tetramers to ILT2 and ILT4 receptors . European Journal of Immunology . 30 . 12 . 3552–3561 . December 2000 . 11169396 . 10.1002/1521-4141(200012)30:12<3552::AID-IMMU3552>3.0.CO;2-L . 42462661 . free .
18. Lee N, Ishitani A, Geraghty DE . HLA-F is a surface marker on activated lymphocytes . European Journal of Immunology . 40 . 8 . 2308–2318 . August 2010 . 20865824 . 3867582 . 10.1002/eji.201040348 .
19. Ishitani A, Sageshima N, Lee N, Dorofeeva N, Hatake K, Marquardt H, Geraghty DE . Protein expression and peptide binding suggest unique and interacting functional roles for HLA-E, F, and G in maternal-placental immune recognition . Journal of Immunology . 171 . 3 . 1376–1384 . August 2003 . 12874228 . 10.4049/jimmunol.171.3.1376 . free .
20. Burian A, Wang KL, Finton KA, Lee N, Ishitani A, Strong RK, Geraghty DE . HLA-F and MHC-I Open Conformers Bind Natural Killer Cell Ig-Like Receptor KIR3DS1 . PLOS ONE . 11 . 9 . e0163297 . 2016-09-20 . 27649529 . 5029895 . 10.1371/journal.pone.0163297 . 2016PLoSO..1163297B . Rachel Louise . Allen . free .
21. Jordier F, Gras D, De Grandis M, D'Journo XB, Thomas PA, Chanez P, Picard C, Chiaroni J, Paganini J, Di Cristofaro J . 6 . HLA-H: Transcriptional Activity and HLA-E Mobilization . Frontiers in Immunology . 10 . 2986 . 2020 . 32010122 . 6978722 . 10.3389/fimmu.2019.02986 . free .
22. Persson G, Jørgensen N, Nilsson LL, Andersen LH, Hviid TV . A role for both HLA-F and HLA-G in reproduction and during pregnancy? . Human Immunology . 81 . 4 . 127–133 . April 2020 . 31558330 . 10.1016/j.humimm.2019.09.006 . HLA-G Special Issue . 203568247 .
23. Allan DS, Lepin EJ, Braud VM, O'Callaghan CA, McMichael AJ . Tetrameric complexes of HLA-E, HLA-F, and HLA-G . Journal of Immunological Methods . 268 . 1 . 43–50 . October 2002 . 12213342 . 10.1016/s0022-1759(02)00199-0 .
24. Goodridge JP, Burian A, Lee N, Geraghty DE . HLA-F and MHC class I open conformers are ligands for NK cell Ig-like receptors . Journal of Immunology . 191 . 7 . 3553–3562 . October 2013 . 24018270 . 3780715 . 10.4049/jimmunol.1300081 .
25. Burian A, Wang KL, Finton KA, Lee N, Ishitani A, Strong RK, Geraghty DE . HLA-F and MHC-I Open Conformers Bind Natural Killer Cell Ig-Like Receptor KIR3DS1 . PLOS ONE . 11 . 9 . e0163297 . 2016-09-20 . 27649529 . 5029895 . 10.1371/journal.pone.0163297 . 2016PLoSO..1163297B . free .
26. Ishigami S, Arigami T, Okumura H, Uchikado Y, Kita Y, Kurahara H, Maemura K, Kijima Y, Ishihara Y, Sasaki K, Uenosono Y, Natsugoe S . 6 . Human leukocyte antigen (HLA)-E and HLA-F expression in gastric cancer . Anticancer Research . 35 . 4 . 2279–2285 . April 2015 . 25862890 .
27. Harada A, Ishigami S, Kijima Y, Nakajo A, Arigami T, Kurahara H, Kita Y, Yoshinaka H, Natsugoe S . 6 . Clinical implication of human leukocyte antigen (HLA)-F expression in breast cancer . Pathology International . 65 . 11 . 569–574 . November 2015 . 26332651 . 10.1111/pin.12343 . free .
28. Zhang X, Lin A, Zhang JG, Bao WG, Xu DP, Ruan YY, Yan WH . Alteration of HLA-F and HLA I antigen expression in the tumor is associated with survival in patients with esophageal squamous cell carcinoma . International Journal of Cancer . 132 . 1 . 82–89 . January 2013 . 22544725 . 10.1002/ijc.27621 . 23526646 .
29. Lin A, Zhang X, Ruan YY, Wang Q, Zhou WJ, Yan WH . HLA-F expression is a prognostic factor in patients with non-small-cell lung cancer . Lung Cancer . 74 . 3 . 504–509 . December 2011 . 21561677 . 10.1016/j.lungcan.2011.04.006 .
30. Xu Y, Han H, Zhang F, Lv S, Li Z, Fang Z . Lesion human leukocyte antigen-F expression is associated with a poor prognosis in patients with hepatocellular carcinoma . Oncology Letters . 9 . 1 . 300–304 . January 2015 . 25435979 . 4246689 . 10.3892/ol.2014.2686 .
31. Morandi F, Cangemi G, Barco S, Amoroso L, Giuliano M, Gigliotti AR, Pistoia V, Corrias MV . 6 . Plasma levels of soluble HLA-E and HLA-F at diagnosis may predict overall survival of neuroblastoma patients . BioMed Research International . 2013 . 956878 . 2013-11-21 . 24350297 . 3856218 . 10.1155/2013/956878 . free .
32. Zhang J, Pan L, Chen L, Feng X, Zhou L, Zheng S . Non-classical MHC-Ι genes in chronic hepatitis B and hepatocellular carcinoma . Immunogenetics . 64 . 3 . 251–258 . March 2012 . 22015712 . 10.1007/s00251-011-0580-2 . 14765632 .
33. Jucaud V, Ravindranath MH, Terasaki PI, Morales-Buenrostro LE, Hiepe F, Rose T, Biesen R . Serum antibodies to human leucocyte antigen (HLA)-E, HLA-F and HLA-G in patients with systemic lupus erythematosus (SLE) during disease flares: Clinical relevance of HLA-F autoantibodies . Clinical and Experimental Immunology . 183 . 3 . 326–340 . March 2016 . 26440212 . 4750595 . 10.1111/cei.12724 .
34. Richardson SJ, Rodriguez-Calvo T, Gerling IC, Mathews CE, Kaddis JS, Russell MA, Zeissler M, Leete P, Krogvold L, Dahl-Jørgensen K, von Herrath M, Pugliese A, Atkinson MA, Morgan NG . 6 . Islet cell hyperexpression of HLA class I antigens: a defining feature in type 1 diabetes . Diabetologia . 59 . 11 . 2448–2458 . November 2016 . 27506584 . 5042874 . 10.1007/s00125-016-4067-4 .